JP2022518232A5 - - Google Patents
Info
- Publication number
- JP2022518232A5 JP2022518232A5 JP2021541578A JP2021541578A JP2022518232A5 JP 2022518232 A5 JP2022518232 A5 JP 2022518232A5 JP 2021541578 A JP2021541578 A JP 2021541578A JP 2021541578 A JP2021541578 A JP 2021541578A JP 2022518232 A5 JP2022518232 A5 JP 2022518232A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- diazo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794231P | 2019-01-18 | 2019-01-18 | |
| US62/794,231 | 2019-01-18 | ||
| PCT/US2020/014149 WO2020150639A1 (en) | 2019-01-18 | 2020-01-17 | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518232A JP2022518232A (ja) | 2022-03-14 |
| JP2022518232A5 true JP2022518232A5 (enExample) | 2023-01-27 |
| JP7574198B2 JP7574198B2 (ja) | 2024-10-28 |
Family
ID=71614516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541578A Active JP7574198B2 (ja) | 2019-01-18 | 2020-01-17 | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220117938A1 (enExample) |
| EP (1) | EP3911310A4 (enExample) |
| JP (1) | JP7574198B2 (enExample) |
| KR (1) | KR20210117303A (enExample) |
| CN (1) | CN113438947A (enExample) |
| AU (1) | AU2020208637A1 (enExample) |
| BR (1) | BR112021014112A2 (enExample) |
| CA (1) | CA3126822A1 (enExample) |
| EA (1) | EA202191992A1 (enExample) |
| IL (1) | IL284907A (enExample) |
| MX (1) | MX2021008546A (enExample) |
| SG (1) | SG11202107317WA (enExample) |
| WO (1) | WO2020150639A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291850A (en) * | 2019-10-03 | 2022-06-01 | Dracen Pharmaceuticals Inc | Lyophilized composition containing (s)-isopropyl 2-((s)-2-acetamido-3-(h1-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and use thereof |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| CN116601140A (zh) | 2020-10-02 | 2023-08-15 | 羿尊生物医药股份有限公司 | 用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途 |
| AU2021361970A1 (en) * | 2020-10-15 | 2023-06-15 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| CN114621120B (zh) * | 2020-12-10 | 2023-11-03 | 深圳先进技术研究院 | 一种don前药分子、前药激活化合物和前药激活体系 |
| WO2022232565A1 (en) * | 2021-04-29 | 2022-11-03 | The Johns Hopkins University | Prodrugs of 6-diazo-5-oxo-l-norleucine |
| WO2022261117A1 (en) * | 2021-06-07 | 2022-12-15 | Dracen Pharmaceuticals, Inc. | Combination therapy with a don prodrug and a tigit inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN105873606B (zh) | 2013-09-11 | 2020-12-29 | 米迪缪尼有限公司 | 用于治疗肿瘤的抗b7-h1抗体 |
| US20150252434A1 (en) | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| DK3328827T3 (da) * | 2015-07-31 | 2023-10-02 | Univ Johns Hopkins | Prodrugs af glutaminanaloger |
| WO2017023791A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Glutamine antagonists for the treatment of cognitive deficits |
| CA2994165A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Methods for cancer and immunotherapy using glutamine analogues, including don |
| WO2017040666A2 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US20200405879A1 (en) * | 2017-04-20 | 2020-12-31 | Adc Therapeutics Sa | Combination therapy |
| DK3692015T3 (da) * | 2017-10-06 | 2022-11-21 | Univ Johns Hopkins | Hidtil ukendte glutaminantagonister og anvendelser deraf |
-
2020
- 2020-01-17 BR BR112021014112-0A patent/BR112021014112A2/pt not_active IP Right Cessation
- 2020-01-17 CN CN202080013742.1A patent/CN113438947A/zh active Pending
- 2020-01-17 EA EA202191992A patent/EA202191992A1/ru unknown
- 2020-01-17 SG SG11202107317WA patent/SG11202107317WA/en unknown
- 2020-01-17 MX MX2021008546A patent/MX2021008546A/es unknown
- 2020-01-17 JP JP2021541578A patent/JP7574198B2/ja active Active
- 2020-01-17 KR KR1020217026015A patent/KR20210117303A/ko not_active Ceased
- 2020-01-17 US US17/423,819 patent/US20220117938A1/en not_active Abandoned
- 2020-01-17 CA CA3126822A patent/CA3126822A1/en active Pending
- 2020-01-17 WO PCT/US2020/014149 patent/WO2020150639A1/en not_active Ceased
- 2020-01-17 AU AU2020208637A patent/AU2020208637A1/en not_active Abandoned
- 2020-01-17 EP EP20741361.8A patent/EP3911310A4/en not_active Withdrawn
-
2021
- 2021-07-18 IL IL284907A patent/IL284907A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7190549B2 (ja) | Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法 | |
| Seyedin et al. | Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models | |
| JP2019506403A5 (enExample) | ||
| CN109640985A (zh) | Hdac抑制剂和pd-l1抑制剂的组合疗法 | |
| FI3365368T3 (fi) | Tgf-beeta-1:tä sitovia immunoglobuliineja ja niiden käyttö | |
| JP2020536109A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP2023507190A5 (enExample) | ||
| JP2021510697A5 (enExample) | ||
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| JP2015534579A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2016128399A5 (enExample) | ||
| JP2018531278A6 (ja) | 癌のための併用療法 | |
| JP2018531278A (ja) | 癌のための併用療法 | |
| RU2017136709A (ru) | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr | |
| JP2018519324A5 (enExample) | ||
| US20200399377A1 (en) | Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen | |
| JP2024504260A5 (enExample) | ||
| JP2021521274A5 (enExample) | ||
| JP2024016209A5 (enExample) | ||
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| JP2021511344A5 (enExample) | ||
| JP2023524359A5 (enExample) | ||
| JP2022549156A5 (enExample) |